Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Current Deferred Revenue (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Current Deferred Revenue data on record, last reported at $2.6 million in Q2 2025.

  • For Q2 2025, Current Deferred Revenue changed N/A year-over-year to $2.6 million; the TTM value through Jun 2025 reached $2.6 million, changed N/A, while the annual FY2024 figure was $3.3 million, 40.0% down from the prior year.
  • Current Deferred Revenue reached $2.6 million in Q2 2025 per MRVI's latest filing, down from $3.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $119.2 million in Q1 2021 and bottomed at $1.8 million in Q3 2024.
  • Average Current Deferred Revenue over 5 years is $16.8 million, with a median of $4.8 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: crashed 96.9% in 2022, then skyrocketed 78.11% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $10.2 million in 2021, then crashed by 69.76% to $3.1 million in 2022, then soared by 78.11% to $5.5 million in 2023, then plummeted by 40.0% to $3.3 million in 2024, then dropped by 21.21% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $2.6 million in Q2 2025, $3.5 million in Q1 2025, and $3.3 million in Q4 2024.